PDCD1 and metastatic melanoma: It was another breakthrough of immune checkpoint blockade that nivolumab (BMS-936558) and pembrolizumab, two fully human anti-PD-1 monoclonal antibodies, were approved by FDA for the treatment of unresectable or metastatic melanoma in 2014.